Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression

Abba, Martı́n C.; Drake, Jeffery; Hawkins, Kathleen A.; Hu, Yuhui; Sun, Hongxia; Notcovich, Cinitia; Gaddis, Sally; Şahin, Ayşegül; Baggerly, Keith A.; Aldaz, C. Marcelo

doi:10.1186/bcr899

Cited by 130 publications

(115 citation statements)

References 46 publications

Supporting

Mentioning

106

Contrasting

Order By: Relevance

“…Loss of heterozygosity in this region was observed in several solid tumors, including breast cancer, ovarian cancer, lung cancer and BeckwithWiedemann syndrome (Negrini et al, 1995;Tran and Newsham, 1996;Catchpoole et al, 1997;Lu et al, 1997;O'Briant and Bepler, 1997;Karnik et al, 1998). We detected downregulated IFITM1 expression in 20 out of 28 clinical hepatoma samples, consistent with the reported transcriptional downregulation of IFITM1 in low-grade diffuse astrocytomas and breast cancer (Huang et al, 2000;Abba et al, 2004). Recently, it was suggested that high IFITM1 expression correlated with improved survival in chronic myeloid leukemia patients (Akyerli et al, 2005).…”

Section: Discussionsupporting

confidence: 79%

See 1 more Smart Citation

IFITM1 plays an essential role in the antiproliferative action of interferon-γ

et al. 2006

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 79%

“…Moreover, it has been reported that transcriptional expression of IFITM1 is downregulated in low-grade diffuse astrocytomas and breast cancer (Huang et al, 2000;Abba et al, 2004). In this study, we report that IFITM1 mediates the antiproliferative effect of IFN-g and arrests cell proliferation in a p53-dependent manner.…”

Section: Introductionsupporting

confidence: 58%

IFITM1 plays an essential role in the antiproliferative action of interferon-γ

et al. 2006

View full text Add to dashboard Cite

“…12,13,32,37 However, 42% of the ERa-negative tumors showed high, and 17% of the ERa-positive tumors showed low FOXA1 expression; and FOXA1 levels were inversely correlated with lympho-vascular invasion, even after adjustment for ERa status. These data suggest that at least some of FOXA1 activities in breast cancer are ERa-independent.…”

Section: Discussionmentioning

confidence: 99%

FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer

Wolf

Bose

Williamson

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

The transcription factor Forkhead-box A1 (Foxa1), a member of the FOX class of transcription factors, has been implicated in the pathogenesis of lung, esophageal and prostate cancers. We have recently identified transcriptional activation of p27 by FOXA1. In this study, we analyzed the activities and expression pattern of FOXA1 in breast cancer. Forced expression of FOXA1 inhibited clonal growth of breast cancer cell lines, and FOXA1 levels inversely correlated with growth stimuli. In the estrogen receptor (ER)-positive MCF-7 cells, FOXA1 increased p27 promoter activity and inhibited the ER pathway activity. Analysis of FOXA1 expression in breast tissue arrays revealed significantly higher expression in pure ductal carcinomas in situ compared to invasive ductal carcinomas (IDC); and in IDC, high expression of FOXA1 was associated with favorable prognostic factors. Yet, FOXA1 expression was noted in a subset of the ER-negative tumors. Taken together, our findings suggest a growth inhibitory role for FOXA1, and identify it as a novel, potential prognostic factor in breast cancer. ' 2006 Wiley-Liss, Inc.Key words: FOXA1; breast cancer; p27; estrogen receptorThe FOX class of transcription factors, now counting more than 100 members, is characterized by an evolutionary conserved 110 amino-acid DNA binding domain, known as the forkhead (FH) domain.1,2 Three FOXA proteins, FOXA1, FOXA2 and FOXA3, are currently known and each shares a conserved structure, consisting of DNA binding domain and 4 transactivating regions, 2 in the C-terminal side of the protein and 2 in its N-terminus.3-5 FOXA1 is expressed in the liver, pancreas, bladder, prostate, colon, lung as well as mammary gland and can bind to the promoters of more than 100 genes associated with metabolic processes, regulation of signaling and the cell cycle.1,2,6 In mice, embryos carrying a homozygous null mutation for FOXA1 develop normally to term but suffer from severe postnatal growth retardation and hypoglycemia followed by death between postnatal days 2 and 12. 7,8 High expression of FOXA1 has been reported in various tumors, including lung, esophageal and prostate cancer. 9,10 In prostate cancer, current data suggest a growth inhibitory role for FOXA1. While FOXA1 is expressed in both preneoplastic lesions and adenocarcinomas, its expression is associated with markers of differentiation, and transfection assays revealed that FOXA1 had an inhibitory effect on the androgen receptor. 11 Moreover, FOXA1 null prostate shows hyperplastic lesions. 11In breast cancer, studies of global gene expression revealed high expression of FOXA1 mRNA, often in association with the expression of the estrogen receptor alpha (ERa), 12,13 but also showed FOXA1 expression in a subset of ER-negative tumors.14 Among the ER-positive tumors, expression of FOXA1 mRNA was noted in tumors that showed favorable outcomes. 15 In accordance with a growth inhibitory role of FOXA1 in breast cancer, studies in MCF-7 cells suggested downregulation of FOXA1 mRNA levels following estrogen stimulat...

show abstract

“…Collagen III disrupts formation of dense, organized collagen I networks, resulting in softer ECM [94]. Loss of collagen III in mouse models is associated with tumor aggressiveness [94], though Col III is often observed to be overexpressed with increasing tumor grade [20,81,82,95]. Furthermore, reductions in collagen I density via TGFβ blockade likewise suggest that altering collagen network structure is a potential therapeutic target [96].…”

Section: Microstructure Biomechanics and Crosslinkingmentioning

confidence: 99%

The extracellular matrix in breast cancer predicts prognosis through composition, splicing, and crosslinking

Robertson

2016

Experimental Cell Research

View full text Add to dashboard Cite

The extracellular matrix in breast cancer predicts prognosis through composition, splicing, and crosslinking a b s t r a c tThe extracellular matrix in the healthy breast has an important tumor suppressive role, whereas the abnormal ECM in tumors can promote aggressiveness, and has been linked to breast cancer relapse, survival and resistance to chemotherapy. This review article gives an overview of the elements of the ECM which have been linked to prognosis of breast cancers, including changes in ECM protein composition, splicing, and microstructure. Published by Elsevier Inc.

show abstract

Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression

Cited by 130 publications

References 46 publications

IFITM1 plays an essential role in the antiproliferative action of interferon-γ

IFITM1 plays an essential role in the antiproliferative action of interferon-γ

FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer

The extracellular matrix in breast cancer predicts prognosis through composition, splicing, and crosslinking

Contact Info

Product

Resources

About